Combo of Tools IDs Alcohol Use in Transplant Patients
(HealthDay News) – The Alcohol Use Disorders Identification Test for alcohol consumption (AUDIT-c) combined with urinary ethyl glucuronide (uEtG) testing improves the detection of alcohol consumption in liver transplant candidates and recipients, according to a study published online April 2 in Liver Transplantation.
Salvatore Piano, MD, from the University of Padova in Italy, and colleagues evaluated uEtG, AUDIT-c, serum ethanol, urinary ethanol, carbohydrate-deficient transferrin (CDT), and other indirect markers of alcohol consumption in 121 liver transplant candidates (LTCs) and liver transplant recipients (LTRs).
The researchers found alcohol consumption in 30.6% of patients. The strongest marker of alcohol consumption was uEtG (odds ratio, 414.5; P<0.0001), which showed a more accurate prediction rate of alcohol consumption compared to CDT (area under the receiver operating characteristic curve [AUROC], 0.94 vs. 0.63; P<0.0001) and AUDIT-c (AUROC, 0.94 vs. 0.73; P<0.0001). An even higher accuracy in detecting alcohol consumption was seen with the combination of uEtG with AUDIT-c, compared to the combination of CDT and AUDIT-c (AUROC, 0.98 vs. 0.8; P<0.001). In patients with a negative AUDIT-c, uEtG was the most useful marker for detecting alcohol consumption.
"In conclusion, the association of AUDIT-c and uEtG improves the detection of alcohol consumption in LTCs and LTRs," the authors write.